Quantcast
Last updated on April 20, 2014 at 1:20 EDT

Latest Phosphate binders Stories

2014-03-18 20:20:37

DUBLIN, March 18, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/plhkq8/calcium) has announced the addition of the "Calcium Carbonate-Precipitated (CAS 471-34-1) Market Research Report" [http://www.researchandmarkets.com/research/plhkq8/calcium ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Calcium Carbonate-Precipitated (CAS 471-34-1) Market Research Report presents comprehensive...

2013-10-17 08:30:43

CINCINNATI, Oct. 17, 2013 /PRNewswire/ -- Prasco Laboratories announced today it has signed an exclusive distribution and supply agreement with Shire for the Authorized Generic of FOSRENOL® (lanthanum carbonate) Chewable Tablets. As part of the agreement, Prasco will market Lanthanum Carbonate Chewable Tablets in the U.S. in 500 mg, 750 mg, and 1000 mg strengths under the Prasco label in response to the first generic entrant. "Today's announcement is the latest example of Prasco and Shire...

2013-09-10 23:27:21

Approval of This Novel Phosphate Binder Will Be a Major Milestone for the Company Cary, NC (PRWEB) September 10, 2013 BioLink Life Sciences, Inc., a biopharmaceutical innovator, announced today that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application for PiLo™ (calcium succinate capsules) for review. PiLo™ is the Company's patented phosphate binder for the treatment of elevated blood phosphate in patients with end stage renal disease (ESRD). Upon...

2013-08-16 12:22:19

DUBLIN, August 16, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/584zgp/calcium_carbonate) has announced the addition of the "Calcium carbonate (CAS 471-34-1) Market Research Report 2013" [http://www.researchandmarkets.com/research/584zgp/calcium_carbonate ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Calcium carbonate (CAS 471-34-1) Market Research Report 2013 presents...

2013-08-08 23:03:37

RenaGum™ is a new approach to helping people with chronic kidney disease (CKD) maintain normal phosphate levels. It is the first medical food that is not another pill or tablet you need to swallow, but a pleasant tasting sugar-free chewing gum made with natural ingredients. Hunt Valley, MD (PRWEB) August 08, 2013 Mastix Medica, an innovative specialty manufacturer of dietary supplements and functional foods, has introduced RenaGum™, a novel medical food that helps patients with...

2013-06-05 08:30:12

Sevelamer Continues to Lead in Patient Share and Calcium Acetate Use has Declined Compared to Last Year, According to a New Report from BioTrends Research Group EXTON, Pa., June 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use of phosphate binders in the U.S. has declined in both the hemodialysis and peritoneal dialysis setting over the past two years. (Logo:...

2013-04-19 14:26:14

Dietary restriction may be the best way to reduce phosphate's negative effects on the heart Highlights: -The phosphate binder sevelamer carbonate did not improve cardiovascular measures in patients with early chronic kidney disease. -For now, reducing dietary intake of phosphate may be the best way for these patients to reduce the mineral's negative effects on the heart. -High phosphate levels–in kidney disease patients and in the general population–increase the risk of...

2013-01-28 08:28:24

NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced successful top-line results from the long-term Phase 3 study of Zerenex(TM) (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. In this study, Zerenex met the study's primary endpoint, described below, demonstrating a highly...

2013-01-27 20:20:16

NEW YORK, Jan. 27, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) will host a conference call tomorrow, Monday, January 28, at 8:00am ET to review the top-line results from the Phase 3 long-term study component of its Phase 3 registration program of Zerenex((TM)) (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. Keryx...

2013-01-07 08:29:42

NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that its Japanese partner, Japan Tobacco Inc. (JT), has filed its New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). The NDA filing is supported by efficacy and safety data from several successfully completed Phase 3 studies in...